haloperidol has been researched along with epalrestat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Acevedo, O; Dasararaju, G; Devadasan, V; Halakova, D; Jayaprakash, V; Kovacikova, L; Mohd Siddique, MU; Mondal, SK; Prnova, MS; Shilkar, D; Stefek, M; Thakur, A; Yasmin, S | 1 |
2 other study(ies) available for haloperidol and epalrestat
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Non-carboxylic acid inhibitors of aldose reductase based on N-substituted thiazolidinedione derivatives.
Topics: Aldehyde Reductase; Animals; Caco-2 Cells; Catalytic Domain; Dogs; Enzyme Inhibitors; Humans; Hypoglycemic Agents; Madin Darby Canine Kidney Cells; Male; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Structure; Protein Binding; Rats, Wistar; Structure-Activity Relationship; Thiazolidinediones | 2021 |